Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations

Rhea-AI Summary

Precision BioSciences, Inc. (DTIL) promotes Naresh Tanna to Vice President of Investor Relations to enhance and expand its IR program. Tanna, with over 18 years of diverse experience in Oncology, Infectious Diseases, and Rare Diseases, will lead communications with shareholders. His promotion follows Mei Burris' elevation to Senior Director of Finance and Corporate Controller in September 2023.

- Dedicated Senior-Level Function will Enhance and Expand Existing Strategic IR Program

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that Naresh Tanna, Chief of Staff to the CEO, has been promoted to Vice President of Investor Relations to enhance and expand its IR program and communications with shareholders.

“Since joining Precision BioSciences as my Chief of Staff at the start of 2022, Naresh has had a unique vantage point to Precision’s management team and board of directors with a key role in executing our day-to-day operations and strategy,” said Michael Amoroso, Chief Executive Officer of Precision BioSciences. “Naresh’s breadth of experience before Precision, along with the deep knowledge gained since joining the company, position him to successfully lead communications with our shareholders. He has made important contributions to our investor relations activities starting with Precision’s 2023 In Vivo R&D Day and, we look forward to the impact he will make in this expanded role.”

Naresh assumes leadership of the investor relations function following the promotion of Mei Burris, CPA to Senior Director of Finance and Corporate Controller in September 2023. Naresh will continue to serve as an integral member of the Senior Leadership Team helping to drive Precision’s corporate strategy into fruition as it advances its wholly owned in vivo gene editing programs towards clinic.

Mr. Tanna joined Precision BioSciences in January 2022 as Chief of Staff to the CEO. He brings over 18 years of diverse experiences across Oncology, Infectious Diseases and Rare Diseases across treatment modalities. Mr. Tanna has held roles in global oncology marketing at Amgen and Eli Lilly and global hematology at Abbvie and Celgene, focusing on marketing, strategy and execution across commercial and development stage products. Earlier in his career, he held life sciences consulting roles at Trinity Partners and Clarkston Consulting. Mr. Tanna holds an M.B.A. from the IESE Business School and a B.S. in Biomedical Engineering and Political Science from Rutgers School of Engineering.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the suitability of ARCUS nucleases for gene elimination, insertion, excision and other gene editing approaches. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “target,” “will,” “would,” or the negative thereof and similar words and expressions.

Forward-looking statements are based on management’s current expectations, beliefs and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding to advance our programs; risks associated with our capital requirements, anticipated cash runway, requirements under our current debt instruments and effects of restrictions thereunder, including our ability to raise additional capital due to market conditions and/or our market capitalization; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; our or our collaborators’ or other licensees’ ability to identify, develop and commercialize product candidates; pending and potential product liability lawsuits and penalties against us or our collaborators or other licensees related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators’ or other licensees’ development of product candidates; our or our collaborators’ or other licensees’ ability to advance product candidates into, and successfully design, implement and complete, clinical or field trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; our ability to obtain an adequate supply of T cells from qualified donors; delays or difficulties in our and our collaborators’ and other licensees’ ability to enroll patients; changes in interim “top-line” and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; our or our licensees’ ability to obtain orphan drug designation or fast track designation for our product candidates or to realize the expected benefits of these designations; our or our collaborators’ or other licensees’ ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the rate and degree of market acceptance of any of our product candidates; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate executives and personnel; effects of system failures and security breaches; insurance expenses and exposure to uninsured liabilities; effects of tax rules; effects of the COVID-19 pandemic and variants thereof, or any pandemic, epidemic, or outbreak of an infectious disease; the success of our existing collaboration agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events; effects of sustained inflation, supply chain disruptions and major central bank policy actions; market and economic conditions; risks related to ownership of our common stock, including fluctuations in our stock price; our ability to meet the requirements of and maintain listing of our common stock on Nasdaq or other public stock exchanges; and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website under SEC Filings at investor.precisionbiosciences.com.

All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240213840695/en/

Investor and Media Contact:

Naresh Tanna

Vice President of Investor Relations

naresh.tanna@precisionbiosciences.com

Source: Precision BioSciences, Inc.

FAQ

Who has been promoted to Vice President of Investor Relations at Precision BioSciences?

Naresh Tanna has been promoted to Vice President of Investor Relations at Precision BioSciences.

What is Precision BioSciences' ticker symbol?

The ticker symbol for Precision BioSciences is DTIL.

What is Naresh Tanna's background and experience?

Naresh Tanna has over 18 years of diverse experiences across Oncology, Infectious Diseases, and Rare Diseases. He has held roles in global oncology marketing at Amgen and Eli Lilly, global hematology at Abbvie and Celgene, and life sciences consulting roles at Trinity Partners and Clarkston Consulting.

When did Naresh Tanna join Precision BioSciences?

Naresh Tanna joined Precision BioSciences in January 2022 as Chief of Staff to the CEO.

What academic qualifications does Naresh Tanna hold?

Naresh Tanna holds an M.B.A. from the IESE Business School and a B.S. in Biomedical Engineering and Political Science from Rutgers School of Engineering.